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Abstract
Background: Estrogen plays a critical role in breast cancer. Thereafter, endocrine therapy is a
standard of care in patients with breast carcinoma, expressing ER or PR.
Case presentation: Herein we report the case of a 53-year old patient, who developed
cholestasis and vasculitis during the treatment with tamoxifen. This toxicity was reversable after
the removal of the drug. Thereafter she continued adjuvant treatment for breast carcinoma with
anastrazole. Since tamoxifen has been widely indicated for patients with breast carcinoma, we did
a literature review, looking for other cases with this type of toxicity.
Conclusion: This case is the third with vasculitis informed in the literature, but the first one that
additionally developed cholestasis and arthritis. Although it is rare, we discuss the indication of this
drug in the actual era, where aromatase inhibitors offer a better security profile.
Background
Breast cancer is the most common cause of cancer death
in women worldwide. Rates vary about fivefold around
the world, but they are increasing even in regions that
until recently had low rates of disease [1] Endocrine treat-
ment is indicated in hormone-sensitive patients.
Tamoxifen is an oral antiestrogen, first used in metastatic
breast cancer in the early 1970s. Large clinical trials were
initiated in the late 1970s and early 1980s to test the
drug's role as adjuvant therapy in early stage breast cancer.
Observations of marked decreases in the development of
contralateral breast cancer among tamoxifen recipients
suggested potential for the drug in chemoprevention of
breast cancer. The most recent analysis of the Early Breast
Cancer Trialists' Collaborative Group (EBCTCG) which
included information on 37,000 women in 55 trials of
adjuvant tamoxifen, published in 2005, confirms the
value of this oral antiestrogen. Among women with ER-
positive disease, the reduction in the recurrence rate and
in the breast cancer death rate are highly significant either
after 1–2-year or 5-year use of tamoxifen, but are greater
in the latter. This indirect evidence that 1–2 years is less
effective than 5 years of tamoxifen in ER-positive disease
is highly significant for recurrence, and for breast cancer
mortality, and is supported by the directly randomised
comparisons of different tamoxifen durations. In patients
with ER-negative disease, tamoxifen may or not produce
some benefit either after 1–2 years or 5 years of tamoxifen.
For women with tumors of unknown ER status the bene-
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fits are slightly weaker than those for women with ER-pos-
itive disease [2].
In regard to its chemopreventive properties, a number of
prevention trials with tamoxifen have shown a 48%
reduction in ER-positive cancers [3]. Based on these find-
ings, the United States Preventive Services Task Force rec-
ommended women with risk factors for breast cancer
should discuss the potential benefits and harms of
tamoxifen with their doctors [4].
The use of adjuvant tamoxifen has been associated with
certain toxic effects. The most important is the develop-
ment of endometrial cancer that occurs at a rate that is 2
to 7 times greater than that observed in untreated women
[5,6]. Tamoxifen is also associated with an increased inci-
dence of deep venous thrombosis, pulmonary emboli and
stroke [7-11]. Other less frequent encountered side effects
are benign ovarian cysts, [12] and ophthalmologic altera-
tions [13]. Toxic effects of short-term toxic effects of
tamoxifen may include vasomotor and gynecologic symp-
toms such as vaginal discharge or irritation [14]. A case of
vasculitis induced by tamoxifen was reported in 1990 [15]
and since then no other cases are reported in literature.
Case presentation
A 53-year old woman was admitted to emergency room
with one week history of purpuric lesions limited to both
legs, accompanied by paresthesias, very painful arthral-
gias which confined her to wheel chair and distal edema
in both lower extremities. She had a previous history of
modified mastectomy with axillary lymphadenectomy for
a retroareolar, canalicular breast carcinoma 6 months
before, whose histological diagnosis was a ductal carci-
noma measuring 4.5 cm of diameter, estrogen and proges-
terone receptor-positive and HER2 negative. She received
adjuvant radiation and started tamoxifen 20 mg daily four
months before admission. At the clinical examination,
she had several purpuric papular lesions in both distal
extremities, some were confluent, within a 1 cm diameter
on the left external heel. Arthritis was also present in both
ankles and knees. Liver function tests demonstrated a
cholestatic damage, with increase of alkaline phosphatase
(196; normal: 40–150 U/L), GGT (213; normal> 12–43),
SGPT (249; normal 5–66 U/L), SGOT (110; normal 9–55
U/L); other liver tests, and the rest of laboratory, including
SMA-18, blood cytology, coagulation studies, viral hepati-
tis infection markers, antinuclear antibodies, coagulation
tests and crioaglutinines were normal. Tumor markers,
including CA15-3 were negative or normal. Liver ultra-
sound showed none focal lesions and was considered nor-
mal. Histopathology analysis of skin biopsies showed
deposits of fibrinoid material in the walls and infiltration
by lymphocytes and neutrophils in dermis vessels, which
was diagnosed as vasculitis.
Tamoxifen was withdrawn and methylprednisolone at 1 g
daily was administered during 3 days. Thereafter, 0.5 mg/
kg prednisone was indicated during 7 days and subse-
quently decreased. Lesions disappeared after one week.
Currently she is alive and well receiving anastrazole.
Discussion
Tamoxifen is a widely used drug in the treatment of breast
cancer. Endometrial cancer and thrombosis-related phe-
nomena are well-known side-effects of this drug, how-
ever, because of its ample use it is important to be aware
of other uncommon toxicities. Although skin changes
caused by tamoxifen were reported in 19% of tamoxifen
treated patients [15], and also published medical litera-
tureidentified occasional reports of skin reactions (urti-
caria) in patients receiving tamoxifen [16-18], the
development of purpuric vasculitis due to tamoxifen is
extremely unsual, since only two cases of purpuric vascu-
lits have been reported in the literature [19,20]. In the first
case [19], also a mild elevation of aspartate aminotrans-
ferase level was documented, but neither a clear choles-
tatic damage or arthritis; a clear drug-relation was
documented, since vasculitis disappeared after tamoxifen
withdrawal, and reappeared when this drug was newly
indicated. The second case [20] was recently published,
and describes the dermal vasculopathic changes in a
patient who required tamoxifen, after progression with
fulvestrant, but, as the first one, none other clinical mani-
festations, including liver function tests abnormalities or
arthritis were present. The authors concluded that the
quick resolution of this toxicity after tamoxifen discontin-
uation strongly supported a cuase-effect in this patient. A
comprehensive list of the cases reported in literature to
date is detailed in Table 1.
Other severe toxicities, such as liver toxicity, thromboem-
bolism and endometrial carcinoma have also been
described [5,6,8,10,21]. Among drug-induced cholestasis,
estrogens, anabolic steroids and structurally similar con-
geners such as tamoxifen are well-described causes of this
syndrome [21], whereas acute inflammatory arthritis has
only been reported in three cases [22]. The cases of acute
inflammatory polyarthritis in association with tamoxifen
had none liver damage, and also neither skin lession. Our
case report is unique in the sense that the patient showed
the association of purpuric vasculitis, cholestasis and
arthritis. Tamoxifen, a non-steroidal antiestrogen, has
been used in the treatment of breast cancer since the early
1970s. Tamoxifen binds to estrogen receptor (ER) and
inhibits estradiol binding to ER, resulting in decreased
tumor cell proliferation and cell death. In addition to anti-
tumor responses, tamoxifen can also exert antiangiogenic
effects. According with the Stockholm trial [23],
tamoxifen was considered the standard of care for adju-
vant treatment in node-negative postmenopausalWorld Journal of Surgical Oncology 2007, 5:9 http://www.wjso.com/content/5/1/9
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patients, with improvement of DFS and overall survival.
Thereafter the NSABP B-14 trial [24] confirmed this
results and informed a 12% absolute difference in DFS, a
28% reduction in treatment failure, and 22% reduction in
mortality after 5 years of treatment. This nonsteroidal
estrogen antagonist was the only approved adjuvant treat-
ment of hormone positive breast carcinoma. However,
initial results from the ATAC trial [25] demonstrated a
clearly benefit of the use of anastrazole in such patients,
with prolongation of the time to recurrence, a 58% reduc-
tion of primary contralateral breast cancers, as well as,
increase of DFS. A longer follow-up of these patients [26],
confirmed the benefit of this aromatase inhibitor. Other
aromatase inhibitors have also been evaluated in this set-
ting: letrozole, administered as an extended therapy, after
5 years-tamoxifen, showed a lower risk of recurrence by
43% and improvement of the estimated 4-year DFS by 6%
and OS by 2% [27]. The Intergroup Exemestane Study also
demonstrated that the addition of exemestane (as sequen-
tial therapy) after tamoxifen increased the DFS to 91.5%,
although the OS was not modified. These results have
demonstrated a clearly benefit of aromatase inhibitors,
compared with tamoxifen, as adjuvant treatment for
breast carcinoma, and also a better sequrity profile, since
a significant reduction in hot flushes, vaginal discharge,
vaginal bleeding, ishcemic cerebrovascular events, and
endometrial cancer has been informed. On the other
hand, these drugs exhibit more musculoskeletal disorders,
osteoporosis and fractures. On basis of the important effi-
cay, with a better sequrity profile, they should be consid-
ereded as the first line of adjuvant treatment in patients
with breast carcinoma, in particular anastrazol, which is
the only drug approved by the FDA in the adjuvant set-
ting, without a previous tamoxifen therapy, that may
avoid severe side effects, as occurred in this patient.
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